Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Entry into a Material Definitive Agreement

ME Staff 8-k
-
0

Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement

On December12, 2017, Blueprint Medicines Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs& Co. LLC and Morgan Stanley& Co. LLC, as representatives of the underwriters named therein (collectively, the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 3,703,704 shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at a price to the public of $81.00 per share (the “Offering Price”). After deducting the underwriting discounts and commissions and estimated offering expenses, the Company expects to receive net proceeds from the Offering of approximately $283.0 million. The Company has also granted the Underwriters a 30-day option to purchase up to an additional 555,555 shares of Common Stock at the Offering Price.

The Offering was made to the Company’s effective automatic shelf registration statement on FormS-3ASR (File No.333-216573), as supplemented by a prospectus supplement dated December12, 2017, filed on December 13, 2017. The Offering is expected to close on December15, 2017, subject to the satisfaction of customary closing conditions.

A copy of the Underwriting Agreement is attached as Exhibit1.1 to this Current Report on Form8-K and is incorporated herein by reference. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.

A copy of the legal opinion of Goodwin Procter LLP relating to the legality of the issuance and sale of the shares in the Offering is attached as Exhibit5.1 to this Current Report on Form8-K.

Item 8.01 Other Events

On December11, 2017, the Company issued a press release announcing the Offering, and on December12, 2017, the Company issued a press release announcing the pricing of the Offering. Copies of these press releases are attached to this Current Report on Form8-K as Exhibits 99.1 and 99.2, respectively, and are each incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

See the ExhibitIndex which immediately follows the hereto, which ExhibitIndex is incorporated herein by reference.


Blueprint Medicines Corp Exhibit
EX-1.1 2 a17-27816_4ex1d1.htm EX-1.1 Exhibit 1.1   Execution Version   Blueprint Medicines Corporation   Common Stock,…
To view the full exhibit click here

About Blueprint Medicines Corporation (NASDAQ:BPMC)

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options. The Company has developed a small molecule drug pipeline in cancer and a genetic disease. The Company’s drug candidate, BLU-285, targets KIT Exon 17 mutants and PDGFRa D842V, which are abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. It is engaged in developing BLU-285 for patients with systemic mastocytosis (SM), a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor (GIST). Its drug candidate, BLU-554, targets FGFR4, a kinase that is aberrantly activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma (HCC).